Continuous-batch RNA manufacturing: Coming to a lab near you

Fast-track your RNA therapy without compromising quality.

Partner with specialist RNA CDMO Exothera and access the benefits of Ntensify™ – the world-first continuous-batch RNA production platform developed by sister company Quantoom Biosciences. 

Let’s get started

Ntensify™: Game-changing continuous-batch RNA production

Continuous process. Unlimited progress.

With access to leading-edge technology and an expert CDMO partner, you can accelerate the progress of your RNA therapy from the earliest stages of drug development and beyond with confidence. By standardizing and automating our process, we remove scale-up and process development steps, helping you reduce costs and achieve higher quality and yields. 

Dedicated specialists, committed to service

De-risk your decision to transform your RNA manufacturing journey with a committed and experienced team of scientific problem-solvers by your side at every step. Partnering with you to understand your project, our dedicated team works hard to provide tailored solutions and offer the right level of support you need to advance to your critical milestones. 

Ultimate flexibility for every phase

Access our gold-standard, RNA production platform and allow our expert team to guide you as your project progresses on its journey to market. Offering you a flexible partnership at flexible prices, we give you the right level of support you need to progress your product through each critical milestone with ease. 

Why partner with Exothera for your RNA manufacturing journey?

By harnessing the expertise of Exothera and the power of Ntensify™, we enable you to:

Cut typical clinical production timelines by approximately half 

Bypass time-intensive process development and scale-up activities

Reduce your cost of goods (COGs) by half

Achieve high post-purification yields with consistently high quality

Lets talk

Introducing: Endless opportunities for your RNA therapy

From vaccines to personalized cancer medicines, our scalable platform and technical capabilities enable you to develop and manufacture high-quality nucleic acid-based therapies. 

A faster alteRNAtive

By harnessing automation for greater efficiencies, Ntensify™ reduces clinical development timelines – enabling you to reach your next milestone with remarkable speed.

Increased quality

Achieve higher yields at consistently higher quality with a solution that limits user handling to mitigate the potential for variability.

Designed for any scale

Our ecosystem of solutions supports you from single batch or continuous large-scale production for large-scale vaccine manufacturing. With kits for R&D in academia, variant screening and GMP production, we support your transition from early-stage development to commercialization.

A team with a track record

With access to the team that invented the Nfinity and the expertise of our scientific and regulatory teams to guide you, you can confidently advance your product through the critical milestones on its journey to patients.

Open communication at every stage

Partnering with you to understand your project, our dedicated team works hard to provide tailored solutions and offer the right level of support you need to advance to your critical milestones.

Flexible partnership and pricing

Whether you decide to onboard the technology into your own facility or let us take the reins long-term, we flex with you to give you the right support and capabilities as your product progresses.

Accessible pricing

We strive to make our offering accessible to companies of all sizes, regardless of your stage in drug development. Early-stage companies can access our ‘fast track’ package for research use, with the option for flexible pricing models. 

Case study: Seamless scalability of mRNA vaccine production, leveraging NtensifyTM platform

If the benefits of automated, continuous-batch RNA manufacturing sound too good to believe, read our sister company Quantoom Bioscience’s latest case study to access recent study results on the efficiency benefits that can and have been achieved.

Upscaling a rabies vaccine from R&D to commercial scale

The case study explores how Exothera, in partnership with Quantoom Biosciences, worked with a customer to seamlessly upscale the production of their rabies vaccine from R&D to commercial scale. The study demonstrates the efficiency and scalability of the NtensifyTM process from small-scale production to automated large-scale execution. 

Download to access the comparative study and view the results and potential benefits to your mRNA journey. 

Download

Want to learn more?

View our press release here

About Exothera 

Exothera is a Belgium and US-based CDMO delivering customized process development and GMP manufacturing services for viral vectors (AAV, AV, HSV, LVV, …) and mRNA or saRNA projects. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide bespoke process optimization and GMP clinical and commercial production of viral vectors and nucleic acids. 

Learn More

Send Us a Message

First Name*
Last Name*
Company Name*
Message

Case Study: Seamless scalability of mRNA vaccine production leveraging NtensifyTM platform

First Name*
Last Name*
Company Name*